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Many naturally occurring and man-made chemicals present in the environment possess estrogenic activity. Examples include plant and fungal
products, pesticides, plasticizers, and other agricultural and industrial chemicals. These environmental estrogens as well as endogenous ovarian
estrogens are thought to initiate their physiological actions in target tissues largely via interactions with a nuclear receptor system. The resultant
estrogen-receptor complex in turn affects transcription via its interactions with nucleotide sequences known as estrogen response elements (EREs)
present in the regulatory regions of hormone responsive genes. A "consensus" ERE sequence GGTCAnnnTGACC was originally identified in the
vitellogenin genes of birds and amphibians, but it is now clear that most naturally occurring EREs differ from this sequence in one or more bases.
We and others have obtained both in vivo and in vitro data suggesting a differential interaction of receptor complexes containing different ligands
with the multiple EREs present in mammalian systems. This raises the possibility that the toxicity of environmental estrogens may arise in part from
a differential pattern of ERE activation by environmental compounds relative to endogenous ovarian estrogens. The experimental basis for such a
paradigm and its toxicological implications are discussed in this paper. - Environ Health Perspect 103(Suppl 7):29-33 (1995)
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Introduction
It has been recognized for some time that a
number of chemicals in the environment
possess estrogenic activity in a variety of
biological systems. These compounds
include plant and fungal products, pesti-
cides, plasticizers, estrogenic agents admin-
istered to livestock, and a variety of other
chemicals (1,2). As these agents are capable
ofperturbing the normal hormonal milieu
in humans and other animals, they can
be properly considered as environmental
toxicants. Similarly, it is clear that the
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pharmacological use of ovarian estrogens
and synthetic compounds such as diethyl-
stilbestrol (DES) can cause toxicity, e.g.,
the endometrial cancer seen in women
receiving unopposed estrogens (3) and
reproductive tract abnormalities in women
exposed to DES in utero (4). For ease of
discussion, we will refer to all such envi-
ronmental and pharmacological com-
pounds as environmental estrogens. What
then is the mechanism of toxicity of such
environmental estrogens?
One straightforward possibility is that
these compounds alter the physiological
patterns oftarget tissue function, prolifera-
tion, and development normally regulated
by ovarian estrogens such as estradiol. The
basic idea here is that exposure to these
compounds is simply like being exposed to
too much of an endogenous estrogen pro-
duced by the ovary. For example, environ-
mental estrogens could interact with
estrogen receptors in the hypothalamic/
pituitary axis to alter circulating gonado-
tropin levels and affect reproductive func-
tion in both males and females. Such
effects on differentiated function have been
suggested as a possible mechanistic basis
for the decrease in human sperm counts
recently reported (5). A second example
would be the increase in endometrial can-
cer resulting from the pharmacological use
of unopposed estrogens for hormone
replacement therapy in postmenopausal
women (3). Since estrogens increase endo-
metrial proliferation, this toxicity could
result simply from an increased level of
DNA replication by increasing the proba-
bility of introducing mutations into the
genome due to mismatch errors. Alterna-
tively, one could envision that estrogens
might be promoters and act by expanding
a clone ofaltered endometrial cells to form
a tumor. In either case, estrogens would be
acting by an extension of their physiologi-
cal action to stimulate endometrial prolif-
eration in preparation for implantation.
Similarly, a third possibility is that inap-
propriate exposure to estrogens such as
DES during development alters target cell
differentiation and predisposes the tissue to
subsequent tumor development. This again
could be viewed as a case in which toxicity
results largely from an extension ofnormal
hormonal function-in this case the con-
trol oftissue differentiation.
It is implicit in this paradigm that envi-
ronmental estrogens interact with the
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estrogen receptor to increase or decrease a
biological response in a manner similar to
that of endogenous ovarian steroids. In
other words, all estrogens (environmental
or endogenous) function in the same way
to convert the receptor from an inactive
state to an active state. The basic paradigm
here is that the receptor is like a simple
switch, i.e., it is "off' in the absence ofan
estrogen but is turned "on" byligand bind-
ing, and all ligands convert the receptor to
the same basic "on" state.
In the nucleus of target cells, estrogen
receptors interact with the so-called estro-
gen response elements (EREs) of target
genes. The EREs are DNA sequences of
approximately a dozen nucleotides that
enable the receptor to bind to target genes.
The activated receptor bound to the ERE
then interacts with other nuclear factors
(e.g., other transcription factors) and the
resulting interactions enhance or repress
transcription. In this model the basic func-
tion of the ERE is to serve as the binding
site on the DNA for the receptor-ligand
complex, and little thought has been given
to other possible regulatory roles for this
element (6-8).
Given this perspective most research to
date on environmental estrogens has
focused on a) identifying environmental
compounds that bind to the estrogen recep-
tor, b) analyzing their pharmacokinetic
profiles and bioaccumulation, c) developing
bioassays predictive for estrogenic actions
such as cellular proliferation, and d) defi-
ning the relationships between their chemi-
cal structures, receptor-binding properties,
andsubsequentbiological effects.
More recently however, we have begun
to consider the pharmacology of estrogen
action from a somewhat different perspec-
tive. Our work and that ofothers suggests
that the EREs of different genes may be
differentially activated by the complex of
the estrogen receptor (ER) with any given
estrogen, and the complexes formed
between the ER and different estrogens
may exhibit selective patterns ofERE acti-
vation in vivo. This led us to consider a
paradigm in which one may view the ERE
and associated factors (e.g., chromosomal
proteins, other transcription factors, etc.)
as a functional receptor or estrogen recep-
tor-receptor (ERR) for the traditional
estrogen receptor, and the complex
between the traditional receptor and an
estrogenic ligand as the agonist in the sys-
tem. While clearly speculative, this para-
digm suggests some additional issues
related to estrogenic substances in the envi-
ronment. In the remainder ofthis paper we
will discuss some of the experimental
findings that led us to consider this para-
digm and its potential implications for the
toxicity ofenvironmental estrogens.
Estrogen Response
Elements Are Diverse
The paradigm noted above originally
occurred to us from ourstudies on the EREs
of hormone target genes. By way of back-
ground, the majority ofexperimental studies
on EREs have used the so-called consensus
ERE (c-ERE) originally identified in the
vitellogenin genes ofxenopus and chickens
(9,10). This element is a 13-mer palin-
dromic sequence, GGTCAnnnTGACC,
that binds the estrogen receptor as a homo-
dimer, confers estrogen inducibility to target
genes, and is located in the 5'-flanking
region of the endogenous genes (9-12).
More recently, we and numerous other
groups initiated studies to identify the EREs
in other genes regulated physiologically
byestrogens.
Our own work has focused on c-fos, c-
jun, and other members ofthe AP-1 family
oftranscription factors, whose expression is
regulated by physiological levels of estra-
diol in intact animals. Transcript levels of
these genes are rapidly activated in the
rodent uterus following in vivo administra-
tion of estradiol, and several studies sug-
gested that this was a direct transcriptional
effect ofthe hormone (13,14). Based upon
the location of EREs in the vitellogenin
gene and other genes, we initially searched
the 5'-upstream region ofthe murine c-fos
gene for a functional element but were
unsuccessful. We next examined other
regions of the gene and identified a
functional ERE in the 3'-untranslated
region of the gene approximately 6 kilo-
bases (kb) from the start site of transcrip-
tion (15). This element binds the estrogen
receptor in cell-free band-shift assays
(15,16) and confers hormonal responsive-
ness to both homologous and heterologous
promoters (15). Interestly, thefos ERE has
the sequence GGTCAnnnCAGCC, which
contains one-half site (GGTCA) identical
to that in the c-ERE but a second halfsite
that is quite different (TGACC in the c-
ERE vs CAGCC in thefosERE).
More recently, we have identified a
functional ERE in the rat c-jun gene that
binds the estrogen receptor and confers hor-
monal inducibility (17). This element is
located in the single exon of the jun gene
and has the sequence GCAGAnnnTGACC.
This sequence again has one-half site
(TGACC) that is identical to that in the
c-ERE, but the other halfsite differs in 3 of
5 positions.
Our results with c-fos and c-jun indi-
cated that the EREs for these genes vary
considerably in sequence and location from
that of the consensus element and
prompted us to examine the literature for
EREs located in other hormone responsive
genes. Table 1 lists a number ofEREs that
have been reported to date. Upon viewing
this information, it was somewhat surpris-
ing to us to realize that the consensus ERE
is present only in the vitellogenin gene of
xenopus and chicken and that all other ele-
ments identified to date contain one to
three changes in the 10 bases comprising
the palindromic half sites of the c-ERE.
The most common pattern, seen in all but
two cases, is an element with one-half site
identical to the c-ERE, and a second non-
identical halfsite.
Table 1. Identified estrogen response elements.
Source Species Sequenceb Locationc References
Vitellogenin A2 Xenopus GGTCANNNTGACCa 5'-P (10)
Vitellogenin II Chicken GGTCANNNTGACCa 5'-P (9)
Ovalbumin Chicken GGTCA 5'-P (18)
Calbindin Rat GGTCANNNTGATC 5'-P (19)
Prolactin Rat GGTCANNNTGTCC 5'-p (20)
LHb Rat GGACA(N)5TGTCC 5'-p (21)
c-jun Rat GCAGANNNTGACC Exon (17)
Creatinine kinase B Rat GGTCANNNCACCC 5'-P (22)
Uteroglobin Rabbit GGTCANNNTGCCC 5'-P (23)
MCF-7 pS2 Human GGTCANNNTGGCC 5'-P (24)
Oxytocin Human GGTGANNNTGACC 5'-P (25)
Progesterone receptor Human GGTCGNNNTGACT 5'-* (26)
c-fos Human CGGCANNNTGACC 5'-P (27)
c-fos Mouse GGTCANNNCAGCC 3'-UIT (15)
Lactoferrin Mouse GGTCANNNTAACC 5'-P (28)
This sequence represents the consensus. bUnderlined bases represent deviation from the consensus.in the case of
ovalbumin gene, only a fully conserved first half-site is required for ER mediated induction. cLocations are 5'-P=5',
promoter region; 3'-UT=3', untranslated region; 5'-*=5', untranslated and overlapping initiation oftranscription.
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Dose-Response Relationships
for Estrogenic Responses
Are Variable
What then are the possible biological
ramifications of this diversity of hormone
response elements? One obvious possibility
is that different EREs interact differentially
with the estrogen receptor. We have
recently examined the relative binding
affinity ofthe estrogen receptor to oligode-
oxynucleotides containing the sequences of
the consensus ERE and the c-fos ERE in an
in vitro band-shift assay system (16). The
results indicate that there is about a 10-fold
difference in affinity ofthese two naturally
occurring elements. Similarly, another set
of measurements we recently performed
indicate that there is a 3- to 5-fold differ-
ence in the relative affinity of the estrogen
receptor for the c-fos and c-jun ERE
sequences (unpublished observations).
These results are consistent with several
studies illustrating that minimal alterations
(i.e., changes in one to two nucleotides) in
hormone response elements can dramati-
cally alter receptor binding and the ability
to confer hormone inducibility to reporter
constructs (29-31).
This raises the interesting possibility
that differential affinities of the estrogen
receptor for different EREs could lead to
different dose-response curves for activa-
tion of different genes and hence lead to
different dose-response curves for various
biological responses to estrogens. This pos-
sibility prompted us to examine the litera-
ture for such differential dose-response
relationships.
As much as 20 years ago, Clark and his
colleagues (32-34) emphasized that differ-
ent responses of the rodent uterus exhibit
different dose-response curves for estrogens.
For example, early tissue responses occur-
ring 3 hr after estradiol administration
exhibit a different dose-response curve
than growth responses occurring at later
times (32-34). This was thought to be due
to the differential interaction of the estro-
gen receptor with different "nuclear accep-
tor sites" present in uterine chromatin (35)
since specific ERE sequences had not been
defined at this time. In other studies, Clark
and his colleagues (33) also showed that
different uterine responses (e.g., glucose
oxidation vs organ weight) occurring at the
same time (3 hr) after estradiol treatment
also exhibit different dose-response curves.
A possible explanation ofthese data is that
ER interactions with EREs having different
receptor affinities are responsible for the
different dose-response curves observed.
Interpretation ofsuch studies is compli-
cated, however, because they used complex
processes (e.g., glucose oxidation, tissue
weight, etc.) as indices of estrogen action,
and these processes are likely to be affected
by many parameters that are difficult to
analyze in vivo. More recently, however,
several studies have examined the dose-re-
sponse curves for different genes using the
rodent uterus as an experimental system.
For example, Pentecost et al. (36) noted a
substantial difference in the dose-response
curves for estradiol induction of actin and
creatinine kinase. Similarly, we (37)
observed approximately a 4-fold difference
in the dose-response curves for induction
of c-fos and c-jun in the uterus. A conse-
quence of this difference is that a dose of
estradiol (0.4 fg/kg) which increases c-jun
expression to only 20 to 25% of its maxi-
mum increases c-fos expression to 75 to
80% ofits maximum.
Given the traditional view of estrogen
receptors as molecules containing a single
dass ofbinding sites for hormone agonists,
it is very difficult to explain observations
such as thesewithout some type ofdifferen-
tial interaction of the receptor-hormone
complex with different target genes. This
suggested to us a slightly different way to
view the overall control of complex
processes such as endometrial proliferation
that are likely to involve the regulation of
multiple genes by estrogens. One can envi-
sion the basic 13-mer ERE and its associ-
ated factors (e.g., chromosomal proteins,
general transcription factors, nonreceptor
regulatory proteins, etc.) as a functional
complex that we shall refer to as estrogen
receptor-receptor (ERR) in the following
discussion. In a pharmacological sense one
could view the ERR as the functional recep-
tor in the system since it is interactions at
this site that initiate the biological response,
i.e., altered transcription. Concomitantly,
one could view the complex between the
classical receptor and an estrogenic ligand as
the functional agonist. The ERR is thus the
receptor in the pharmacological sense
because it performs the dual roles ofa tradi-
tional receptor, i.e., it binds the agonist and
initiates the biological response. While
somewhat semantic in nature, this para-
digm offers a slightly different conceptual
view ofhow steroids regulate complex bio-
logical processes such as growth and differ-
entiation that probably involve many
different genes.
The ERRs of different estrogen regu-
lated genes have different ERE sequences
(Table 1), and it is reasonable to expect
that they may also contain a diversity of
protein factors in vivo. Ifthe ERRs ofdif-
ferent genes have different structures,
might they also have different properties
such as affinities for the receptor-hormone
complex? Such a paradigm readily allows
one to explain the types of observations
noted above in a system that contains only
a single estrogen receptor. In addition,
such a view of estrogen receptor signaling
has potentially important ramifications for
the toxicityofenvironmental estrogens.
Differential Response Patterns
Produced by Different
Estrogens
In situations where multiple receptor
subtypes exist for a single ligand (e.g., mul-
tiple adrenergic and cholinergic receptors),
pharmacological agents may exhibit selec-
tive patterns of receptor activation. Is it
possible that this can occur in the estrogen
receptor system? For example, do com-
plexes formed between estrogen receptors
and different ligands exhibit different pat-
terns of responses, i.e., do they selectively
activate different ERRreceptors?
A possible example of such differential
selectivity was provided by the studies of
Korach and his colleagues (38-40) who
examined several different uterotropic
responses (induction of DNA synthesis,
glucose-6-phosphate dehydrogenase activ-
ity, and progesterone receptor levels) fol-
lowing in vivo administration ofa series of
diethylstilbestrol (DES) analogs. They
observed that the measured parameters
showed differential patterns of responsive-
ness to the series ofDES analogs and sug-
gested that "the ability of a particular
response to be increased may depend on
the chemical nature of the ligand receptor
complex and its interaction at genomic
sites" (38). These results are certainly con-
sistent with the possibility that complexes
formed between the estrogen receptor and
different DES analogs exhibit selective acti-
vation of distinct ERRs present in various
hormone-responsive genes.
We (41) and Galand et al. (42) studied
the ability ofthe antiestrogen nafoxidine to
block different estrogen-induced responses
in the intact animal and similarly con-
cluded that the ER-nafoxidine complex
exhibited selective interactions with differ-
ent receptor binding sites within target
tissue nuclei. This implied that the anti-
estrogen-receptor complex was able to
block the ER-estradiol complex from
interacting at some nuclear sites but not
others. These intact organ responses were
again somewhat complex and probably
involved activation of multiple genes, but
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more recent examples have appeared in
studies of the effects of the antiestrogen
tamoxifen and analogs of 17p-estradiol on
expression ofindividual genes.
While tamoxifen is an antiestrogen in
some systems, in the rat uterus it acts pri-
marily as an estrogen agonist following
acute administration; several studies have
recently reported that tamoxifen and estra-
diol elicit different patterns ofexpression of
fos and jun family members in this system
(43,44). Some ofthese differences, such as
the length of time that expression of some
genes remains elevated, can be explained on
the basis of pharmacokinetic differences in
the two compounds. However, differences
in the initial patterns ofgene expression are
more difficult to explain without postulat-
ing selective patterns of gene activation by
the estrogen-receptor versus tamoxifen-re-
ceptorcomplexes.
Perhaps the clearest example of this
possiblity to date comes from a recent
series of experiments from Brooks and his
colleagues (45-47). They examined the
ability of a series of estradiol analogs to
bind to the estrogen receptor and elicit bio-
logical responses including induction of
the progesterone receptor, pS2 mRNA,
cathepsin D mRNA, and CAT activity
from reporter constructs containing the
c-ERE. They found clearly different pat-
terns of activation of these responses by
the different estrogen analogs (45-47)
and emphasized the possible biological
significance ofthese observations.
Discussion and
Implications forToxicity
of Environmental Estrogens
Taken together, these findings suggest that
the toxicity of environmental estrogens
could involve a number of factors and
could occur via several related but distinct
mechanisms. The first and most obvious
type of toxicity could be that in which an
environmental estrogen binds to the estro-
gen receptor and produces an estrogenic
response. Toxicity in this case is simply due
to hyperestrogenism, i.e., an extension of
the physiological effects of estrogenic
hormones.
A second type of toxicity, which has
been proposed, is that some estrogens
could also produce toxicities by virtue of
their chemical rather than their hormonal
properties. For example, it has been shown
that administration of estrogens to certain
species leads to the formation of DNA
adducts (48). While not discussed in this
manuscript, we note this possibility
for completeness.
In this manuscript we suggest that a
third, more subtle, type of toxicity could
result if an environmental estrogen pro-
duced an imbalanced estrogenic response
in a target tissue. As discussed above, this
could occur in one of two basic ways.
First, an environmental estrogen such as a
pesticide, a phytoestrogen produced by
plants, a plasticizer, etc., might bind to the
estrogen receptor and produce a different
conformation than estradiol. In this case,
the resulting receptor-ligand complex
might selectively activate/repress estrogen
responsive genes differently than the natu-
rally occurring ovarian hormone. Rather
than simply creating a situation of too
much estrogenic stimulation (which might
be ameliorated by compensatory homeo-
static mechanisms involving the hypothal-
amic-pituitary-gonadal axis), the result
might be a qualitatively distinct state
ofestrogenizatlon.
An imbalanced estrogenic response
might also occur due to the possibility that
estrogenic responses may exhibit different
dose-response curves as illustrated in
Figure 1. Consider for example the relative
stimulation of genes A and B by estradiol
alone or by the presence of estradiol plus
an environmental estrogen. As drawn in
this example, the ratio ofexpression ofA:B
in the presence ofestradiol alone (point E2)
would be approximately 2:1. If, however,
an environmental estrogen is also present
100- Gene
Gene ~~~~~B
E A
I ~~~~~~~~~~~~~~A:B3
2 50-] E2Only -2:1
E2+EE -1:1
E2 E2+EE
'Estrogens'
Figure 1. Hypothetical dose-response curves for two
estrogen-regulated genes in the presence of estradiol
alone (E2) and in the presence of estradiol plus an
environmental estrogen (E2+EE).
in the system (point E2+EE), the ratio of
the two genes products now becomes 1:1.
The net result of such effects could be
an imbalance in the levels of hormonally
regulated growth factors, growth factor
receptors, protooncogenes, and other key
molecules in target cells. Such an altered
profile of regulatory molecules could lead
to abnormal proliferative and differentia-
tive properties ofhormone responsive cells.
This might be particularly deleterious dur-
ing critical developmental periods when
cells may be especially sensitive to alter-
ations in regulatory systems.
Many of the suggestions outlined in
this discussion are admittedly hypothetical
and speculative and will require much
additional work to substantiate or refute.
We also recognize that one can propose
various other models which could equally
well explain some ofthe observations such
as multiple dose-response curves that we
have discussed, e.g., the existence of cell
membrane as well as intranuclear receptors
as suggested by others. However, the ideas
we have discussed stem from ongoing pro-
jects in our labs, which indicate that estro-
gen response elements are more diverse
than we had previously appreciated, and
we elected to offer them here to stimulate
discussion and offer new perspectives on
the possible mechanisms involving the
toxicity ofenvironmental estrogens.
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